Vending machines stocked with naloxone, syringes, and HIV tests are spreading across communities. But do they reach the people who need them most, and what does the evidence say about their impact?

A large prospective cohort study finds no evidence that take-home naloxone increases risky drug use behaviors. Injection frequency, opioid use, benzodiazepine use, and using alone remained unchanged—reinforcing naloxone’s role as a lifesaving harm-reduction tool without unintended risk compensation.